To support the advanced development of candidate therapeutics for a virus covered under the Antiviral Program for Pandemics. The supported research and development activities will progress the therapeutic product development and may include lead optimization, candidate selection, preclinical and IND enabling studies, Chemistry, Manufacturing, and Controls (CMC), IND submission, clinical safety and efficacy assessment. Efforts include a Phase I clinical trial in renal and hepatic impaired patients.